Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia
Status:
Unknown status
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
In view of the diversity of the biology of acute myeloid leukemia (AML) therapy in individual
patients must be individualized. One of the tools for this is molecular-cytogenetic
stratification. It divides patients into five categories (prognostic groups): Favorable,
Intermediate-1, Intermediate-2, Adverse and Very adverse risk. After remission proceedings
are tailored depending on prognostic determined groups.
Research of PALG group in the application in the second line regimen CLAG and CLAG-M proved
high effectiveness of this treatment with low toxicity. Considering experience of PALG
groups, it seems that the use of the schema CLAG early as the second induction therapy is a
viable treatment option.
Phase:
Phase 3
Details
Lead Sponsor:
dr hab. n. med. Agnieszka Wierzbowska
Collaborators:
Copernicus Memorial Hospital Polish Adult Leukemia Group, Gliwice, Poland